Sunshine Biopharma's Adva-27a http://patft.uspto
Post# of 212
Posted On: 11/01/2013 6:38:08 AM
Sunshine Biopharma's Adva-27a
http://patft.uspto.gov/netacgi/nph-Parser?Sec.../8,236,935
It is observed that on this type of cells, the compound 27a has activity comparable with that of etoposide and of podophyllotoxin, and even better on certain cell lines. Also, the compound 32a tested on KB cells has cytotoxicity close to that of etoposide and podophyllotoxin, as well as 37a, 44a, 46a
The IC.sub.50 values are expressed in .mu.M on KB cells in duplicate and were obtained for the 4 leading compounds, i.e. 27a, 32a, 44a, 37a and 46a in parallel with podophyllotoxin and etoposide.
TABLE -US-00003 IC.sub.50 (.mu.M) Podophyllotoxin 1 0.015/0.022 27a 3.45/2.55 32a 0.135/0.75 44a 0.323/0.341 37a 0.273/0.306 46a 4.707/6.026 Etoposide 3.509/1.644
For both of these compounds, interesting values are therefore observed in terms of cytotoxicity and of IC.sub.50 for the compounds 32a, 37a and 44a which makes these compounds good chemotherapy agents for treating cancer.
These compounds are presently subject to tests in vivo.
http://patft.uspto.gov/netacgi/nph-Parser?Sec.../8,236,935
It is observed that on this type of cells, the compound 27a has activity comparable with that of etoposide and of podophyllotoxin, and even better on certain cell lines. Also, the compound 32a tested on KB cells has cytotoxicity close to that of etoposide and podophyllotoxin, as well as 37a, 44a, 46a
The IC.sub.50 values are expressed in .mu.M on KB cells in duplicate and were obtained for the 4 leading compounds, i.e. 27a, 32a, 44a, 37a and 46a in parallel with podophyllotoxin and etoposide.
TABLE -US-00003 IC.sub.50 (.mu.M) Podophyllotoxin 1 0.015/0.022 27a 3.45/2.55 32a 0.135/0.75 44a 0.323/0.341 37a 0.273/0.306 46a 4.707/6.026 Etoposide 3.509/1.644
For both of these compounds, interesting values are therefore observed in terms of cytotoxicity and of IC.sub.50 for the compounds 32a, 37a and 44a which makes these compounds good chemotherapy agents for treating cancer.
These compounds are presently subject to tests in vivo.
(0)
(0)